Induction of tumor regression by intratumoral STING agonists combined with anti–programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model

Head and Neck

Volumn 39, Issue 6, 2017, Pages 1086-1094

  Gadkaree, Shekhar K ^a   Fu, Juan ^b   Sen, Rupashree ^b   Korrer, Michael J ^c   Allen, Clint ^b   Kim, Young J ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cyclic dinucleotide (CDN); cyclic di nucleotides; immunotherapy; squamous cell carcinoma; stimulator of interferon gene (STING)

Indexed keywords

ANTINEOPLASTIC AGENT; BLOCKING ANTIBODY; CD8 ANTIGEN; CYCLIC DI GUANINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; PROGRAMMED DEATH 1 LIGAND 1; RESIQUIMOD; STIMULATOR OF INTERFERON GENE AGONIST; UNCLASSIFIED DRUG; CANCER ANTIBODY; MEMBRANE PROTEIN; MPYS PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GROWTH RATE; HEAD AND NECK CANCER CELL LINE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VOLUME; UPREGULATION; ANIMAL; C3H MOUSE; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; HEAD AND NECK TUMOR; IMMUNOLOGY; IMMUNOTHERAPY; INTRALESIONAL DRUG ADMINISTRATION; PATHOLOGY; PROCEDURES; RANDOMIZATION; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTIBODIES, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FEMALE; HEAD AND NECK NEOPLASMS; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C3H; PROGRAMMED CELL DEATH 1 RECEPTOR; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY;

EID: 85017389955     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.24704     Document Type: Article

References (32)

1. Urruticoechea A, Alemany R, Balart J, Villanueva A, Viñals F, Capellá G. Recent advances in cancer therapy: an overview. Curr Pharm Des 2010;16:3–10.
2. Dimberu PM, Leonhardt RM. Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. Yale J Biol Med 2011;84:371–380.
3. Crittenden MR, Thanarajasingam U, Vile RG, Gough MJ. Intratumoral immunotherapy: using the tumour against itself. Immunology 2005;114:11–22.
4. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521–2532.
5. Chakravarti D, Wong WW. Synthetic biology in cell-based cancer immunotherapy. Trends Biotechnol 2015;33:449–461.
6. de Aquino MT, Malhotra A, Mishra MK, Shanker A. Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett 2015;166:117–133.
7. Libanova R, Becker PD, Guzmán CA. Cyclic di-nucleotides: new era for small molecules as adjuvants. Microb Biotechnol 2012;5:168–176.
8. Nelson MH, Diven MA, Huff LW, Paulos CM. Harnessing the microbiome to enhance cancer immunotherapy. J Immunol Res 2015;2015:368736.
9. Tamayo R, Pratt JT, Camilli A. Roles of cyclic diguanylate in the regulation of bacterial pathogenesis. Annu Rev Microbiol 2007;61:131–148.
10. Burdette DL, Vance RE. STING and the innate immune response to nucleic acids in the cytosol. Nat Immunol 2013;14:19–26.
11. McWhirter SM, Barbalat R, Monroe KM, et al. A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med 2009;206:1899–1911.
12. Sauer JD, Sotelo–Troha K, von Moltke J, et al. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect Immun 2011;79:688–694.
13. Woo SR, Fuertes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014;41:830–842.
14. Vance RE, Isberg RR, Portnoy DA. Patterns of pathogenesis: discrimination of pathogenic and nonpathogenic microbes by the innate immune system. Cell Host Microbe 2009;6:10–21.
15. Leong M, Kanne D, Glickman L, et al. Modified STING-activating cyclic dinucleotide derivatives significantly enhance the anti-tumor activity of therapeutic vaccines. J Immunother Cancer 2013;1(Suppl 1):O20.
16. Fu J, Kanne DB, Leong M, et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med 2015;7:283ra52.
17. Corrales L, Glickman LH, McWhirter SM, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep 2015;11:1018–1030.
18. Vahle AK, Kerem A, Oztürk E, Bankfalvi A, Lang S, Brandau S. Optimization of an orthotopic murine model of head and neck squamous cell carcinoma in fully immunocompetent mice–role of toll-like-receptor 4 expressed on host cells. Cancer Lett 2012;317:199–206.
19. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196–200.
20. Jurk M, Heil F, Vollmer J, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002;3:499.
21. Yin T, He S, Wang Y. Toll-like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model. Mol Med Rep 2015;12:3515–3520.
22. Chandra D, Quispe–Tintaya W, Jahangir A, et al. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol Res 2014;2:901–910.
23. Dubensky TW Jr, Kanne DB, Leong ML. Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants. Ther Adv Vaccines 2013;1:131–143.
24. Yung R, Seyfoddin V, Guise C, et al. Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma. Cancer Chemother Pharmacol 2014;73:639–649.
25. Zeng Q, Peng S, Monie A, et al. Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Hum Gene Ther 2011;22:809–819.
26. Peng S, Monie A, Pang X, Hung CF, Wu TC. Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines. J Biomed Sci 2011;18:21.
27. Demaria O, De Gassart A, Coso S, et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc Natl Acad Sci U S A 2015;112:15408–15413.
28. Baird JR, Friedman D, Cottam B, et al. Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors. Cancer Res 2016;76:50–61.
29. Philpott M, Joseph WR, Crosier KE, Baguley BC, Ching LM. Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Br J Cancer 1997;76:1586–1591.
30. Karaolis DK, Cheng K, Lipsky M, et al. 3′,5′-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation. Biochem Biophys Res Commun 2005;329:40–45.
31. Barker JR, Koestler BJ, Carpenter VK, et al. STING-dependent recognition of cyclic di-AMP mediates type I interferon responses during Chlamydia trachomatis infection. MBio. 2013;4:e00018–e00013.
32. Dubensky TW, Leong ML, Kanne DB, et al. STINGVAX – A novel tumor vaccine with cyclic dinucleotides – can induce potent anti-tumor responses in vivo. Cancer Res 2013;73(8 Suppl): Abstract 4573.